Company Overview and News
Mitrajaya Holdings Bhd (Oct 10, 39 sen) Maintain sell with an unchanged target price (TP) of 38 sen: Mitrajaya Holdings Bhd announced that has secured a RM99.9 million contract for construction of a seven-storey private hospital.
KUALA LUMPUR (Oct 9): Mitrajaya Holdings Bhd has bagged a RM99.9 million contract from International Medical University, Malaysia (IMU) to build a seven-storey private hospital at Bukit Jalil here.
9571 BSMAF 1818
Construction sector Maintain neutral: For the recent second quarter of 2018 results season, seven (54%) out of the 13 contractors under our coverage reported core earnings that were below expectations and six (46%) were within. Contractors are cushioned by healthy order-book levels following the robust job flows in the past two years amid the challenging near-term industry landscape.
9571 5263 9679 BSMAF 8311 1818
KUALA LUMPUR (July 19): Construction and property stocks have rebounded amid increasing likelihood that the Kuala Lumpur-Singapore High Speed Rail (HSR) project is only deferred and not cancelled.
9571 1589 5268
Mitrajaya Holdings Bhd (July 18, 48 sen) Maintain hold with an unchanged target price (TP) of 53 sen: Mitrajaya Holdings Bhd has only managed to secure one new contract worth RM103 million year to date (YTD). Its order book now stands at about RM1.5 billion, translating into 1.5 times cover on financial year 2017 (FY17) construction revenue. Going forward, we expect competition for private-sector jobs to intensify as other contractors start bidding more aggressively within this space due to a reduction in government spending on public infrastructure.
The possible announcement of the full Cabinet line-up could be among the highlights this week, even as businesses continue to cash in on the World Cup 2018 fever and the zero-rated Goods and Services Tax (GST) “tax holiday”. There was no Cabinet meeting last Wednesday (June 13) with Prime Minister Tun Dr Mahathir Mohamad just returning from a work trip in Japan (June 11 and 12) and Hari Raya Puasa festivities on June 15 and 16.
8591 5139 9571 5797 1996 0900 5263 5098 0065 5156
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...